Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Concentration-controlled trials. What does the future hold?

× No keyword cloud information.

41 in total

Review 1. The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies.

Authors: M A Graham; P Workman
Journal: Ann Oncol Date: 1992-05 Impact factor: 32.976

2. Use of adaptive control with feedback to individualize suramin dosing.

Authors: H I Scher; D I Jodrell; J M Iversen; T Curley; W Tong; M J Egorin; A Forrest
Journal: Cancer Res Date: 1992-01-01 Impact factor: 12.701

3. Concentration-controlled versus concentration-defined clinical trials.

Authors: G Levy
Journal: Clin Pharmacol Ther Date: 1993-03 Impact factor: 6.875

4. Therapeutic response in phase I trials of antineoplastic agents.

Authors: E Estey; D Hoth; R Simon; S Marsoni; B Leyland-Jones; R Wittes
Journal: Cancer Treat Rep Date: 1986-09

5. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.

Authors: M A Eisenberger; L M Reyno; D I Jodrell; V J Sinibaldi; K H Tkaczuk; R Sridhara; E G Zuhowski; M H Lowitt; S C Jacobs; M J Egorin
Journal: J Natl Cancer Inst Date: 1993-04-21 Impact factor: 13.506

6. Compliance during treatment of epilepsy.

Authors: I E Leppik
Journal: Epilepsia Date: 1988 Impact factor: 5.864

7. Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity.

Authors: E Fuse; S Kobayashi; M Inaba; H Suzuki; Y Sugiyama
Journal: J Natl Cancer Inst Date: 1994-07-06 Impact factor: 13.506

8. Predictability of phenytoin serum levels by nomograms and clinicians.

Authors: S Vozeh; A Koelz; E Martin; H Magun; G Scollo-Lavizzari; F Follath
Journal: Eur Neurol Date: 1980 Impact factor: 1.710

9. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group.

Authors: R H Mattson; J A Cramer; J F Collins
Journal: N Engl J Med Date: 1992-09-10 Impact factor: 91.245

10. Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).

Authors: D J Kerr; S B Kaye; J Graham; J Cassidy; M Harding; A Setanoians; J C McGrath; W R Vezin; D Cunningham; G Forrest
Journal: Cancer Res Date: 1986-06 Impact factor: 12.701

6 in total

Review 1. Therapeutic drug monitoring of immunosuppressant drugs.

Authors: A Johnston; D W Holt
Journal: Br J Clin Pharmacol Date: 1999-04 Impact factor: 4.335

Review 2. Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials?

Authors: A Grahnén; M O Karlsson
Journal: Clin Pharmacokinet Date: 2001 Impact factor: 6.447

Review 3. Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors: Jasper Dingemanse; Silke Appel-Dingemanse
Journal: Clin Pharmacokinet Date: 2007 Impact factor: 6.447

Review 4. Target concentration strategy for cyclosporin monitoring.

Authors: R G Morris
Journal: Clin Pharmacokinet Date: 1997-03 Impact factor: 6.447

5. Imipramine and mirtazapine are less effective than expected.

Authors: R M Pinder; M Zivkov
Journal: Psychopharmacology (Berl) Date: 1997-02 Impact factor: 4.530

Review 6. Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention.

Authors: David K Metz; Nick Holford; Joshua Y Kausman; Amanda Walker; Noel Cranswick; Christine E Staatz; Katherine A Barraclough; Francesco Ierino
Journal: Transplantation Date: 2019-10 Impact factor: 4.939

6 in total